Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Keeping Track: US FDA Clears Vaxneuvance, Rezurock And Karendia, But Not Teplizumab

Executive Summary

The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker

You may also be interested in...



Bayer Focusing On Early CKD Testing In Kerendia US Launch

The company, which set a list price of $19 per day, sees awareness of diagnosing chronic kidney disease in type 2 diabetes patients as the top challenge for newly approved finerenone in the US.

When Should COVID Vaccines Get Full Approval? US FDA Squeezed By ‘Too Fast’ And ‘Too Slow’ Camps

Some experts argue full FDA approval will help boost vaccination rates that are waning, but others want the agency to mandate studies in special populations and gather other data before making a final decision.

Pfizer’s Prevnar 20 May Have Edge Over Merck’s Pneumococcal Vaccine, ACIP Suggests

CDC advisory committee work group concludes benefits of Merck’s PVC15 in those 65 and older is small while benefits of Pfizer’s PVC20 in those 50 and older is large and in those 65 and older is moderate to large.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS144657

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel